Yong Li

Cardigant Medical, Inc. operates as a development stage biotechnology company. The company focuses on the development of novel biologic compounds and methods for local delivery for the treatment of cardiovascular and peripheral vascular disease. It plans to treat atherosclerosis and plaque stabilization using targeted delivery of large molecule therapeutics based on high density lipoprotein targets. The company also focuses on the use of biologics and combination biologics and devices for the treatment of acute coronary syndromes, carotid stenosis and aortic valve stenosis. Cardigant Medical was founded on April 17, 2009 by Jerett A. Creed and is headquartered in Manhattan Beach, CA.